Algeta ASA, a company focused on the development of novel targeted cancer therapeutics, announces that its research collaboration with Sanofi (previously Genzyme) has been extended. This collaboration, which was announced in April 2011, is focused on evaluating the potential of linking the alpha-emitter thorium-227 to a novel and proprietary antibody from Genzyme.
Over the past 12 months, Algeta and Genzyme have jointly pursued a defined research program and both have contributed resources and expertise to the collaboration. The program and the results produced to date have been reviewed by Algeta and Sanofi (following its 2011 acquisition of Genzyme) and both parties have now decided that the collaboration should continue on the same basis for a further year.
Thomas Ramdahl, Executive Vice President and Chief Technology Officer at Algeta, said: “We have made significant progress in this collaboration with Genzyme and are delighted that it is to continue with the added antibody experience provided by the broader Sanofi team.”
Date: May 1, 2012
Source: Algeta ASA
Filed Under: Drug Discovery